CABAZITAXEL Labatec conc perf 60 mg/6ml flac
7680692330031
CH-69233
L01CD04
07.16.1.
Reimbursement limitations:
CABAZ.LAB.02
En association avec la prednisone ou la prednisolone, pour le traitement de patients atteints d'un …
1 / 3
google
Details
- Product number
- 6923303
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- cabazitaxelum 60 mg, polysorbatum 80, ethanolum anhydricum 1185 mg, macrogolum 300, acidum citricum, nitrogenium, q.s. ad solutionem pro 6 ml.
Articles (1)
Cabazitaxel Labatec 60 mg/6 ml, solution à diluer pour perfusion
Lösung
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
60.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
1185.0 MG | Substance | HNIDK |
|
(N/A)
|
- | Substance | Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | TRGAS |
Reimbursement information
Public price
CHF 2690.90
Specialties list
Yes
Generic
Yes
Reimbursement limitation
SL addition date:
01/12/2023
Authorization holder
Labatec Pharma SA
1217 Meyrin
Authorization information
- Swissmedic authorization number
- 69233
- Drug name
- Cabazitaxel Labatec, solution à diluer pour perfusion
- Galenic form
- KOINF
- ATC Code
- L01CD04
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 20/04/2023
- Authorization expiration date
- 19/04/2028
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- CABAZITAXEL Labatec conc perf 60 mg/6ml flac
- Description (DE)
- CABAZITAXEL Labatec Inf Konz 60 mg/6ml Durchstf
- Market launch
- 20/04/2023
- Narcotic (BTM)
- No